PENDYMAL tumors arise from the ependymal cells of the cerebral ventricles, central canal of the spinal cord, and cortical rests. Although these lesions are relatively uncommon, they present with a spectrum of biological and clinical characteristics that makes specific recommendations regarding their treatment difficult and the assignment of prognostic factors controversial. Heading the list of controversial prognostic factors for ependymal tumors is their histological classification. These tumors may be classified as ependymoma, anaplastic ependymoma, and myxopapillary ependymoma based on criteria established by the World Health Organization (WHO) in 1979 28 and revised in 1985. 19 The prognostic significance of the WHO classification system has been demonstrated in many contemporary series 2, 10, [16] [17] [18] 21, 22 and has extended the findings of older series in which the prognostic significance of tumor grade was first investigated and later demonstrated by Kernohan and FletcherKernohan. 9 Originally, these investigators studied the relationship between patients with rapidly progressive disease and the architectural patterns of their tumors. Lacking sufficient clinical information for these patients, including knowledge of the extent of their resection, the investigators postponed critical analysis of architectural subdivision and malignant propensity. Several years later, Mabon, et al., 14 reanalyzed these and additional cases according to the degree of anaplasia or dedifferentiation based on pleomorphism, hyperchromatism, and the presence of mitotic figures. Four grades of malignancy were described among 57 cases and convincing differences were noted in the survival rate at 3 years, which ranged from 79% for patients with Grade 1 tumors to 9% for those with Grade 4 tumors.
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Although most pathologists recognize the myxopapillary, differentiated, and anaplastic variants of ependymoma, the small number of patients with anaplastic histological tumor types in modern published series (including those demonstrating a survival difference between histological subtypes), the general disagreement regarding the criteria used to grade these tumors, and the generally poor long-term results for all patients with this type of tumor, confound the prognostic significance of histological classification.
In the past, radiation therapy dose and treatment volume recommendations have been made based on tumor loca-ߜ The authors conducted a retrospective review of the clinical and treatment characteristics and outcomes in 28 pediatric patients with anaplastic ependymoma treated with radiation therapy since the advent of computerized tomography (CT) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) . Twelve patients received craniospinal irradiation followed by a boost to the primary site, two received whole-brain radiation therapy followed by a boost to the primary site, and the remaining 14 were treated with focal radiation therapy. The mean dose to the primary site was 5486 cGy. With a median follow-up period of 86 months for the 14 surviving patients (range 31-201 months), the median disease-free survival, measured from the date of diagnosis to the time of recurrence after radiation therapy, was 40 months. The median disease-free survival measured from the start of radiation therapy was 32 months. The median overall survival rate has not been reached and the actuarial estimates of overall survival rates at 5 and 10 years were 56% and 38%, respectively. According to univariate analysis, the disease-free survival rate was significantly improved (p Ͻ 0.01) in patients who underwent a grosstotal resection at diagnosis. Overall survival rates were negatively influenced by treatment with craniospinal and whole-brain irradiation. As calculated by multivariate analysis, increasing dosage to the primary site (p Ͻ 0.05), infratentorial location (p Ͻ 0.01), and gross-total resections (p Ͻ 0.02) resulted in the longest disease-free survival times. All 19 patients in whom treatment failed after radiation therapy suffered a recurrence at the primary site. In addition, one of these patients experienced subarachnoid dissemination. Radiation treatment recommendations for patients with ependymoma have been based on the tumor's location, perceived risk for dissemination, and malignant propensity. The significance of anaplastic histological classification is controversial. Differences in the disease-free and overall survival rates have been demonstrated between ependymomas and anaplastic ependymomas treated in the pre-CT era. The results of this study show that there is no benefit from craniospinal irradiation in this group of patients. tion, histological findings, and the presence of disease beyond the primary site. 21, 22, 27 Craniospinal irradiation was advocated for anaplastic tumors and focal field irradiation for differentiated tumors, but these treatment recommendations are no longer considered standard. To improve our understanding of the outcome of pediatric patients with anaplastic ependymoma, we reviewed 28 consecutive pediatric patients treated at our institution with radiation therapy. This report reviews the clinical characteristics, treatment characteristics, and outcome for these patients and represents one of the largest series of pediatric patients with this histological tumor subtype.
Clinical Material and Methods

Patient Data
The records of 28 patients with assessable intracranial anaplastic ependymoma treated at Memorial Sloan-Kettering Cancer Center between May 1978 and August 1994 were reviewed. The information obtained from these records included the following: date of birth; sex; date of presentation; initial primary tumor imaging study; postoperative cerebrospinal fluid (CSF) analysis and imaging studies of the spine, the extent of resection based on operative reports and postoperative imaging; the use of ventriculoperitoneal (VP) shunting during the initial treatment of the patient; the use and sequencing of radio-and chemotherapy; the radiation doses to the spine, whole brain, and primary site; and the use of additional surgery, radiation therapy, or chemotherapy at the time of treatment failure. The frequencies of the categorical variables and the mean values of the continuous variables are presented in Tables 1 and 2 .
Surgical Treatment
All patients underwent resection as a diagnostic and therapeutic measure at the time of presentation. Resections were performed to the extent that they were compatible with good neurological outcome. Based on the surgeon's intraoperative assessment and postoperative neuroimaging, gross-total and subtotal resections were achieved in 39% and 61% of patients, respectively. A VP shunt was placed during the initial management in 50% of the patients.
Pathological Findings
Tumors were graded as anaplastic ependymoma on the basis of anaplastic features including necrosis and mitoses assessed according to the WHO criteria. 28 
Pretreatment Evaluation
The initial evaluation of the brain included computerized tomography (CT) or magnetic resonance (MR) imaging. Computerized tomography scans were obtained in 21 patients (75%) and MR images were obtained in the remainder. Contrast myelograms were obtained in 12 patients (42%) and spinal MR images in eight (29%). In the remaining eight (29%) we either did not have or were unable to obtain studies of the spine. Cytological studies of CSF were performed in 22 patients (78%).
Radiation Therapy
Twelve patients were treated with craniospinal irradiation followed by a radiation boost to the primary site, and two were treated with whole-brain irradiation followed by a boost to the primary site. Craniospinal irradiation includes irradiation of the entire subarachnoid volume of the central nervous system, both intracranially and intraspinally. Treatment of the intracranial subarachnoid volume is analogous to whole-brain radiation. Thus, a total of 14 patients can be classified as having received whole-brain irradiation as a component of their treatment. The remaining 14 were treated at the primary site only. The average doses to the spine (12 patients), whole brain (14) , and primary site (28 patients) are recorded in Table  2 . The primary site dose is the sum of the whole-brain dose and boost to the primary site for those patients who received craniospinal or whole-brain irradiation. All patients were treated with conventional fractionation (150-180 cGy/day) using either cobalt-60, 6-MV, or 15-MV photons. The craniospinal radiation therapy technique was similar for all patients. Electrons were used to treat the spine in half (six of 12) of the patients treated with craniospinal irradiation. The remainder received craniospinal irradiation with cobalt-60 or 6-MV photons. A boost to the cribriform plate region was administered in one patient.
Chemotherapeutic Treatment
Only five patients (18%) never received chemotherapy, and 29% received chemotherapy prior to radiation therapy. The remaining patients received chemotherapy after radiation therapy; nine (32%) underwent chemotherapy in the adjuvant setting and six (21%) were treated at time of recurrence. The regimens and dosages varied considerably over the time period of the study.
Definitions and Analysis of Disease-Free and Overall Survival
The overall survival time was measured from the date of pathological diagnosis. The disease-free survival time was measured as follows: 1) from the date of pathological diagnosis to failure after radiation therapy; 2) from the date of pathological diagnosis to failure after radiation therapy (Ϯ preirradiation chemotherapy); 3) from the start of radiation therapy to the time of failure after radiation therapy; and 4) from the start of radiation therapy to the time of failure after radiation therapy (Ϯ preirradiation chemotherapy). Failures were described as local, distant (subarachnoid dissemination), or both. The time of failure was determined as the date at which recurrence or progression was confirmed by radiology or biopsy at one of these sites.
Statistical Analysis
Using Cox regression analysis, the clinical and treatment variables were entered in a forward, stepwise manner using probability values of less than 0.05 as criteria for inclusion in the model. 4 For evaluation of endpoint of disease-free and overall survival rates, Kaplan-Meier 8 methodology was used with Wilcoxon-Breslow test statistics. The median follow-up period was 86 months for the 14 surviving patients (range 31-201 months).
Results
Clinical Characteristics
The average age of the 28 patients in this study was 7 years (range 2-20 years). There were 18 males (64%) and 10 females (36%). Gross-total resection was achieved in 11 patients and subtotal resection in 17. Evidence of dissemination beyond the primary site was present in two patients; one showed evidence of spinal metastases on the initial spinal imaging evaluation and one had cytological evidence of dissemination. The primary tumor was located in the supratentorial brain in 14 cases (50%). These data are summarized in Tables 1 and 2 .
Treatment Characteristics
In addition to their initial resection as we have outlined, 14 patients (50%) required VP shunting during their initial management. The mean dose to the primary site was 5486 cGy (range 4000-6000 cGy), whole-brain dosage was 3737 cGy (range 3600-4500 cGy), and spine dosage was 3477 cGy (range 3060-3900 cGy). At the time of their first recurrence after radiation therapy 14 patients underwent additional resection (three gross-total and 11 subtotal resections).
Disease-Free and Overall Survival Times
Nineteen patients (68%) experienced tumor recurrence after radiation therapy. In eight patients receiving chemotherapy prior to radiation therapy the lesion recurred at the primary site prior to radiation therapy, with a median time to recurrence of 13 months (range 2-24 months, 95% confidence interval [CI] ). In four of eight patients radiation therapy subsequently failed, with a median time to failure of 6 months measured from the start of radiation therapy. After preirradiation chemotherapy failed, a repeat resection was performed in seven of the eight patients prior to radiation therapy (three gross-total and three subtotal resections).
The median time to failure after radiation therapy for all patients, measured from the date of pathological diagnosis was 40 months (30-50 months, 95% CI). Measured from the date of pathological diagnosis, the median time to failure was 37 months for patients who did not receive preirradiation chemotherapy and 40 months for those who did. The median time to failure for all patients, measured from the start of radiation therapy, was 37 months (15-59 months, 95% CI). The median time to failure measured from the start of radiation therapy was 37 months for those who did not receive preirradiation chemotherapy (15 of 20 failed) and 6 months for those who did (four of eight failed) .
Prognostic factors for failure following radiation therapy were determined by univariate and multivariate analysis. The disease-free survival rate by univariate analysis was noted to be significantly improved (p Ͻ 0.01) in patients undergoing gross-total resection at diagnosis versus those treated with subtotal resection. When all clinical and treatment variables were included in a multivariate analysis, increasing dose to the primary site, analyzed as a continuous variable (p Ͻ 0.05, r = 0.31), tumors with infratentorial locations (p Ͻ 0.01, r = 0.25), and patients with gross-total resection (p Ͻ 0.02, r = 0.16) were the factors associated with the longest disease-free survival periods. When the factors of dose to the whole brain and spine were excluded from the model, the extent of resection (p Ͻ 0.02, r = 0.16) was the only variable found to be statistically significant for prolonging disease-free survival times.
With a median follow-up period of 86 months for the 14 surviving patients (range 31-201 months), the median survival time has not been reached. The actuarial estimates of survival rates at 5 and 10 years were 56% and 38%, respectively (Fig. 1) . Prognostic factors for decreased survival calculated by univariate analysis included the use of a VP shunt (p Ͻ 0.05), craniospinal irradiation (p Ͻ 0.05), whole-brain radiation therapy (p Ͻ 0.05), and the use of electrons for treatment of the spine (p Ͻ 0.001). By multivariate analysis, only an increased radiation dosage to the primary site (p Ͻ 0.002, r = 0.32), analyzed as a continuous variable, was statistically significant in prolonging overall survival times. When the variables of dosage to the whole brain and spine were removed from the model, the use of electrons to treat the spine (p Ͻ 0.002, r = 0.35) negatively influenced overall survival rates. When the variable of spinal treatment modality was removed from the model, including those indicative of spinal radiation therapy, the use of whole-brain radiation therapy (p Ͻ 0.002, r = 0.30) and chemotherapy at the time of recurrence (p Ͻ 0.01, r = 0.25) negatively influenced survival rates. Similarly, we found on multivariate analysis that adjuvant chemotherapy influenced prolonged survival times compared to chemotherapy given at the time of recurrence (p Ͻ 0.05, r = 0.17). The outcomes and prognostic factors for patients analyzed in this study are summarized in Tables 3 and 4 , respectively.
Patterns of Failure
Recurrence at the primary site was found in all 19 patients in whom radiation therapy failed. Subarachnoid dissemination also occurred in one of these patients.
Discussion
The small number of patients with anaplastic histological findings and the potential for clinical-and treatmentrelated factors to obscure differences in outcome between histological subtypes make the diagnosis of anaplastic ependymoma controversial. Numerous series, all reporting small numbers of tumors, have demonstrated a decrease in survival rates for patients with anaplastic histological findings when compared with patients with the more differentiated form of ependymoma. 10, 17, 22 Additional series have shown marked differences in crude survival rates when comparing the two types even though rigorous statistical methods were not applied. 16, 18 Recent studies in which no difference was demonstrated between histological subtypes have limited follow-up periods. The results of these and other series are summarized in Table 5 .
Factors Prognostic for Disease-Free and Overall Survival Rates
All subtypes of ependymoma are prone to local treatment failure, 11, 12 and radiation therapy administered with or without chemotherapy has been shown to delay the time to local failure. The median time to recurrence varies widely and ranges from 18 months in one series 10 months in the present study. The time to recurrence or disease-free survival is dependent on clinical presentation and treatment-related variables. The location of the primary tumor (supratentorial vs. infratentorial), extent of resection (subtotal vs. gross total), and increasing dosage to the primary site were found to influence disease-free survival rates significantly when combined in a model that included all clinical and treatment-related variables.
Tumor location has been used previously as a guideline for the volume of radiation therapy (neuraxis vs. focal field). 21 Most researchers have reported an increased risk of spinal seeding for infratentorial compared with supratentorial tumors. In our study it is possible that the improved outcome in patients with infratentorial tumors is related to the accessibility of the lesion at the time of initial resection and perhaps at the time of failure. In this study, more patients with infratentorial tumors underwent a gross-total resection than those with supratentorial lesions, and the extent of resection influenced disease-free survival times. The extent of resection has been shown to influence outcome for patients with ependymoma in other series. 3, 7, 17, 24, 26 Although few patients have been treated with doses larger than 5500 cGy, and few dose-response data are available for ependymomas in the literature, 23 our data show that increasing the dosage to the primary site positively influences outcome. The total dosage to the primary site was the only significant treatment-related variable that influenced both disease-free and overall survival rates. Several treatment-related factors were found to have a negative influence on overall survival. Although these factors, including the need for VP shunt placement and whole-brain or neuraxis radiation therapy, may be indicative of advanced or extensive disease for a given group of patients, the rate of gross-total and subtotal resections in this series and the lack of identifiable metastases or failures beyond the primary site contradict such a premise.
Negative Impact of Whole-Brain and Neuraxis Radiation Therapy
In this series, craniospinal irradiation negatively influenced outcome. This finding is important considering the results of previously reported retrospective series. Postoperative radiation therapy, regardless of the treatment volume, has been shown to increase overall survival for patients with ependymoma. 16 However, craniospinal irradiation has previously been shown to have either an unequivocal 21 or mixed 11 benefit. In this series, craniospinal irradiation negatively influenced outcome. This finding, added to the lack of substantial dissemination beyond the primary site and the overwhelming problem of local failure, contraindicates the recommendation of craniospinal irradiation in the absence of dissemination beyond the primary site. Furthermore, the use of craniospinal irradiation is of questionable benefit for patients with disseminated disease that is asymptomatic or minimal in nature, because the doses given to the spine cannot be considered curative and irradiation of the neuraxis may prevent the use of intensive chemotherapy, which has been shown to have some impact on ependymoma in patients with disease beyond the primary site. The negative effects of wide-field radiation therapy have been reported for patients with high-grade gliomas. 13 A reduction in performance status, one of the most significant prognostic indicators for patients with high-grade intracranial neoplasms, may serve as a potential explanation for these findings.
Retrospective View of the Effect of Chemotherapy
Patients who received chemotherapy in the adjuvant setting had a better overall survival rate than patients treated with chemotherapy at the time of recurrence. The optimum regimen and sequencing remain unclear. The response rate to preirradiation combination chemotherapy (vincristine, etoposide, cisplatin, and cyclophosphamide) is being evaluated in newly diagnosed patients with ependymoma who show evidence of residual disease on postoperative imaging. This study, conducted by the Children's Cancer Group, is also intended to test the reproducibility of current histological criteria. Chemotherapy administered prior to radiation therapy in patients with ependymoma has provided mixed results. In a trial of postoperative chemotherapy and delayed radiation in children younger than 3 years of age, 5 24 patients with ependymoma showed a progression-free survival rate of
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Anaplastic ependymoma in pediatric patients 947 58 Ϯ 8% at 1 year, similar to the median time to progression of 13 months experienced by the eight patients in our series who received preirradiation chemotherapy. It is important to know whether preirradiation chemotherapy makes these tumors less responsive to radiation therapy. Conformal radiation therapy may be used to increase safely the dosage to the primary site and high-dose singlefraction irradiation (radiosurgery) may be used to explore different time-dose relationships. Among our eight patients who received preirradiation chemotherapy, all experienced treatment failure at the primary site. A significant difference was noted in time to recurrence from the start of radiation therapy when comparing patients treated with preirradiation chemotherapy with those who had not received this treatment (6 months vs. 37 months). The difference favors the latter group. However, no difference is noted between the two groups when the disease-free survival rate is measured from the date of pathological diagnosis to treatment failure after radiation therapy. Similarly, no difference in the overall survival rate (40 months vs. 37 months) was noted, although the number of patients included in both groups is small.
Overall Survival Rates
The overall survival rate for patients with ependymoma ranges from 20 to 60% in most series. These percentages are derived from reports of 5-year survival rates in patients treated with older as well as contemporary treatment regimens. 1, 2, 17, 18, 21, 22, 25, 27 Our results are similar: the actuarial survival rates at 5 and 10 years were 56% and 38%, respectively. These data demonstrate that 5-year diseasefree survival is a good indicator of treatment efficacy; however, determination of the overvall survival for these patients will require extended follow-up study. This conclusion is further supported by the median time to recurrence (40 months), the predominant mode of failure (local), and the likelihood that many of these patients are amenable to repeat resection at the time of failure. The long-term results in patients with anaplastic ependymoma treated with radiation therapy in the CT era actually do not appear to be any worse than those seen in patients with tumors that are perceived to be "radiocurable" such as medulloblastoma. Our recent report demonstrating poor long-term results for patients with medulloblastoma treated in the CT era (actuarial survival 25% at 10 years) shows the outcome in patients with a tumor that has not only poor long-term local control but a major risk of dissemination beyond the primary site both at presentation and at failure. 15 
Are Histological Findings of Prognostic Significance?
Treatment recommendations for patients with anaplastic ependymoma have been based on the tumor location, perceived risk for dissemination and malignant propensity, and the differences in disease-free and overall survival rates between ependymomas and anaplastic ependymomas treated in the pre-CT era with minimal spinal staging. Our results show that there is no benefit from craniospinal irradiation in a group of patients receiving follow-up care for a median time of 86 months and in whom disease was localized to the primary site in all but two cases (7%). Sufficient numbers of patients are not available from any single reported series to demonstrate that location of an anaplastic tumor influences outcome or that anaplastic tumors have a higher propensity to seed the neuraxis. In the review by Vanuytsel and Brada, 26 tumor grade and location were found to be factors that may influence the risk of spinal seeding, but there was no evidence that failure in the neuraxis was prevented by craniospinal irradiation. The policy of treating anaplastic ependymomas with wide-field irradiation (whole-brain or craniospinal portals) may have contributed to the significantly worse survival rates for these patients when compared with those with well-differentiated ependymomas. This hypothesis is supported by our findings in patients treated with craniospinal or whole-brain radiation therapy in the CT era and the earlier findings of Kovalic, et al., 10 who also demonstrated the detrimental effect of whole-brain radiation therapy. The previously stated policy of treating anaplastic ependymomas with craniospinal irradiation can also be challenged with the hypothesis that craniospinal irradiation does not influence outcome even when the disease has disseminated beyond the primary site. This hypothesis is based on the assumption that cells are commonly disseminated within the subarachnoid space at the time of surgery and that these cells seldom develop into disease that becomes clinically evident. Furthermore, if doses larger than 5000 cGy result in poor long-term local control, it is unlikely that doses that are conventionally administered to the spine with prophylactic or therapeutic intentions would have an impact.
The best treatment regimen for ependymomas demonstrating anaplasia should not be a source of contention for investigators treating this disease. Patients entered into cooperative group trials should be carefully staged and scrutinized for the presence of anaplasia so that if trends indicative of poor outcome become evident, the search for a more effective therapy will not be delayed. Because the number of patients in any given series is small and unless patients are stratified by histological findings as well as other variables shown to have prognostic value, the significance of tumor histology may never be demonstrated. According to the information presented in Table 5 the percentage of patients with anaplastic histological findings ranges from 21 to 61%, and no series contained more than 28 patients.
Conclusions
The diagnosis of anaplastic ependymoma will remain controversial as long as the outcome for all patients with ependymoma remains poor and patients are not stratified by known prognostic factors in prospective studies. The statistically significant differences in overall survival according to histological findings reported in older series may reflect differences in the multimodality treatment and possibly the use of craniospinal radiation therapy. Despite the contention that the subject of histology evokes among treating physicians, efforts should be made to document histological parameters prospectively and meticulously stage patients so that the patterns of failure and outcomes for all patients will be available.
Although the data presented in this study do not resolve the controversy surrounding the issue of anaplastic histol-ogy, we were able to characterize further the expected times to failure and survival for these patients. We also identifed prognostic variables for a relatively large series of patients treated with radiation therapy in the CT era and propose an explanation for the differences in outcome that were noted for different histological subtypes. With these data we confirm that local failure is the primary mode of failure in patients with anaplastic ependymoma and that the recommended dosage and treatment volume for radiation therapy should be similar to that used for patients with high-grade gliomas, with the exception that neuraxis radiation therapy may be reserved for patients with evidence of dissemination. Our data indicate that craniospinal and whole-brain radiation therapy are independently detrimental to patient outcome.
